Drygin Denis 4
4 · Regulus Therapeutics Inc. · Filed Jan 26, 2022
Insider Transaction Report
Form 4
Drygin Denis
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-01-12+400,000→ 400,000 totalExercise: $0.26Exp: 2032-01-11→ Common Stock (400,000 underlying)
Footnotes (1)
- [F1]The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.